𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non–ST-segment elevation acute coronary syndromes patients: An analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome trial

✍ Scribed by Bagai, Akshay; White, Jennifer A.; Lokhnygina, Yuliya; Giugliano, Robert P.; Van de Werf, Frans; Montalescot, Gilles; Armstrong, Paul W.; Tricoci, Pierluigi; Gibson, C. Michael; Califf, Robert M.; Harrington, Robert A.; Newby, L. Kristin

Book ID
122525205
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
264 KB
Volume
166
Category
Article
ISSN
1097-6744

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Early Glycoprotein IIb/IIIa Inhibiti
The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale
✍ Robert P. Giugliano; L. Kristin Newby; Robert A. Harrington; C. Michael Gibson; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB
Randomized evaluation of the efficacy of
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial
✍ David H. Fitchett; Anatoly Langer; Paul W. Armstrong; Mary Tan; Aurora Mendelsoh 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 142 KB